RATIONALE: We have previously reported decreased frontal cortical serotonin2A receptor binding in 30 antipsychotic naïve first-episode schizophrenic patients and a relationship between this binding and positive psychotic symptoms. Until now, no longitudinal studies of serotonin2A receptor in first-episode antipsychotic-naïve schizophrenia patients have reported on the relationship between serotonin2A receptor occupancy and treatment effect after sustained treatment with a specific atypical antipsychotic compound. OBJECTIVES: Here, we measured serotonin2A receptor occupancy with [(18)F]altanserin PET in 15 first-episode antipsychotic-naïve schizophrenia patients before and after 6 months of quetiapine treatment. Moreover, we investigated possible relationships between clinical efficacy, oral dose, and plasma levels of quetiapine RESULTS: Significant nonlinear relationships were found between serotonin2A receptor occupancy, quetiapine dose, and plasma concentration. There was a modest effect on positive symptoms up until a serotonin2A receptor occupancy level of approximately 60%. A receptor occupancy level between 60% and 70% appeared to exert the optimal serotonin2A receptor related treatment effect on positive symptoms whereas no additional serotonin2A receptor associated treatment effect was obtained above a receptor occupancy of 70%. CONCLUSIONS: Taken together, the data point to a therapeutic role of the serotonin2A receptor in the treatment of subgroups of patients with schizophrenia. Specifically, the study indicates a serotonin2A receptor associated therapeutic window on positive symptoms in responding patients in the range between 60% and 70% occupancy in antipsychotic-naïve first-episode schizophrenia. We speculate that non-responding patients need higher dopamine D(2) receptor blockade. Future studies with concurrent measurement of interactions with the dopamine system are, however, warranted to clarify this.
RATIONALE: We have previously reported decreased frontal cortical serotonin2A receptor binding in 30 antipsychotic naïve first-episode schizophrenicpatients and a relationship between this binding and positive psychotic symptoms. Until now, no longitudinal studies of serotonin2A receptor in first-episode antipsychotic-naïve schizophreniapatients have reported on the relationship between serotonin2A receptor occupancy and treatment effect after sustained treatment with a specific atypical antipsychotic compound. OBJECTIVES: Here, we measured serotonin2A receptor occupancy with [(18)F]altanserin PET in 15 first-episode antipsychotic-naïve schizophreniapatients before and after 6 months of quetiapine treatment. Moreover, we investigated possible relationships between clinical efficacy, oral dose, and plasma levels of quetiapine RESULTS: Significant nonlinear relationships were found between serotonin2A receptor occupancy, quetiapine dose, and plasma concentration. There was a modest effect on positive symptoms up until a serotonin2A receptor occupancy level of approximately 60%. A receptor occupancy level between 60% and 70% appeared to exert the optimal serotonin2A receptor related treatment effect on positive symptoms whereas no additional serotonin2A receptor associated treatment effect was obtained above a receptor occupancy of 70%. CONCLUSIONS: Taken together, the data point to a therapeutic role of the serotonin2A receptor in the treatment of subgroups of patients with schizophrenia. Specifically, the study indicates a serotonin2A receptor associated therapeutic window on positive symptoms in responding patients in the range between 60% and 70% occupancy in antipsychotic-naïve first-episode schizophrenia. We speculate that non-responding patients need higher dopamine D(2) receptor blockade. Future studies with concurrent measurement of interactions with the dopamine system are, however, warranted to clarify this.
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: R Lewis; S Kapur; C Jones; J DaSilva; G M Brown; A A Wilson; S Houle; R B Zipursky Journal: Am J Psychiatry Date: 1999-01 Impact factor: 18.112
Authors: Claus Svarer; Karine Madsen; Steen G Hasselbalch; Lars H Pinborg; Steven Haugbøl; Vibe G Frøkjaer; Søren Holm; Olaf B Paulson; Gitte M Knudsen Journal: Neuroimage Date: 2004-12-09 Impact factor: 6.556
Authors: Lars H Pinborg; Karen H Adams; Stig Yndgaard; Steen G Hasselbalch; Søren Holm; Heidi Kristiansen; Olaf B Paulson; Gitte M Knudsen Journal: J Cereb Blood Flow Metab Date: 2004-09 Impact factor: 6.200
Authors: Hans Rasmussen; David Erritzoe; Rune Andersen; Bjorn H Ebdrup; Bodil Aggernaes; Bob Oranje; Jan Kalbitzer; Jacob Madsen; Lars H Pinborg; William Baaré; Claus Svarer; Henrik Lublin; Gitte M Knudsen; Birte Glenthoj Journal: Arch Gen Psychiatry Date: 2010-01
Authors: Anders Ettrup; Sophie da Cunha-Bang; Brenda McMahon; Szabolcs Lehel; Agnete Dyssegaard; Anine W Skibsted; Louise M Jørgensen; Martin Hansen; Anders O Baandrup; Søren Bache; Claus Svarer; Jesper L Kristensen; Nic Gillings; Jacob Madsen; Gitte M Knudsen Journal: J Cereb Blood Flow Metab Date: 2014-04-30 Impact factor: 6.200
Authors: Natalia V Malkova; Joseph J Gallagher; Collin Z Yu; Russell E Jacobs; Paul H Patterson Journal: Proc Natl Acad Sci U S A Date: 2014-06-02 Impact factor: 11.205
Authors: Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen Journal: Med Res Rev Date: 2011-06-14 Impact factor: 12.944